1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
3Department of Nuclear Medicine, Pusan National University School of Medicine, Busan, Korea.
Copyright © 2014 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | Total (n=114) | SUVsum<24.6a) (n=57) | SUVsum≥24.6a) (n=57) | p-value |
---|---|---|---|---|
Age (yr) | 0.248 | |||
<65 | 44 (38.6) | 25 (43.9) | 19 (33.3) | |
≥65 | 70 (61.4) | 32 (56.1) | 38 (66.7) | |
Gender, male | 105 (92.1) | 52 (91.2) | 53 (93.0) | 0.999 |
Performance (ECOG) | 0.616 | |||
0, 1 | 95 (85.6) | 47 (83.9) | 48 (87.3) | |
≥2 | 16 (14.4) | 9 (16.1) | 7 (12.7) | |
Tumor stage | 0.007 | |||
LD | 26 (22.8) | 19 (33.3) | 7 (12.3) | |
ED | 88 (77.2) | 38 (66.7) | 50 (87.7) | |
Chemotherapy cycle | 0.138 | |||
<3 | 17 (17.9) | 6 (12.2) | 11 (23.9) | |
≥3 | 78 (82.1) | 43 (87.8) | 35 (76.1) | |
LDH (units/L) | 0.076 | |||
<420 | 39 (34.2) | 24 (42.1) | 15 (26.3) | |
≥420 | 75 (65.8) | 33 (57.9) | 42 (73.7) | |
NSE (ng/mL) | 0.010 | |||
<28.5 | 31 (37.3) | 21 (51.2) | 10 (23.8) | |
≥28.5 | 52 (62.7) | 20 (48.8) | 32 (76.2) | |
CYFRA21-1 (ng/mL) | 0.014 | |||
<2.4 | 42 (44.7) | 26 (57.8) | 16 (32.7) | |
≥2.4 | 52 (55.3) | 19 (42.2) | 33 (67.3) |
Overall suvival | Progression-free survival | |||
---|---|---|---|---|
|
|
|||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age (<65 yr vs. ≥65 yr) | 7.934 (2.579-24.413) | <0.001 | 0.968 (0.601-1.557) | 0.892 |
Gender (female vs. male) | 2.796 (0.320-24.457) | 0.353 | 7.425 (2.119-26.010) | 0.002 |
Stage (LD vs. ED) | 0.563 (0.190-1.664) | 0.299 | 1.105 (0.614-1.988) | 0.739 |
Chemotherapy (≥3 vs. <3) | 17.701 (4.209-74.445) | <0.001 | 8.148 (3.482-19.066) | <0.001 |
Response to first-line treatment (CR/PR vs. SD/PD) | 4.385 (1.329-14.463) | 0.015 | 1.894 (1.108-3.236) | 0.020 |
LDH (<420 units/L vs. ≥420 units/L) | 1.583 (0.635-3.946) | 0.325 | - | - |
NSE (<28.5 ng/mL vs. ≥28.5 ng/mL) | 2.511 (0.952-6.625) | 0.063 | - | - |
CYFRA21-1 (<2.4 ng/mL vs. ≥2.4 ng/mL) | 1.020 (0.407-2.554) | 0.967 | - | - |
SUVsum (<24.6a) vs. ≥24.6) | 3.970 (1.471-10.715) | 0.006 | 2.296 (1.388-3.797) | 0.001 |
HR, hazard ratio; CI, confidence interval; LD, limited disease; ED, extensive disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; SUVsum, sum of standardized uptake value.
a) The median value of SUVsum.
Variable | Total (n=114) | SUVsum<24.6 |
SUVsum≥24.6 |
p-value |
---|---|---|---|---|
Age (yr) | 0.248 | |||
<65 | 44 (38.6) | 25 (43.9) | 19 (33.3) | |
≥65 | 70 (61.4) | 32 (56.1) | 38 (66.7) | |
Gender, male | 105 (92.1) | 52 (91.2) | 53 (93.0) | 0.999 |
Performance (ECOG) | 0.616 | |||
0, 1 | 95 (85.6) | 47 (83.9) | 48 (87.3) | |
≥2 | 16 (14.4) | 9 (16.1) | 7 (12.7) | |
Tumor stage | 0.007 | |||
LD | 26 (22.8) | 19 (33.3) | 7 (12.3) | |
ED | 88 (77.2) | 38 (66.7) | 50 (87.7) | |
Chemotherapy cycle | 0.138 | |||
<3 | 17 (17.9) | 6 (12.2) | 11 (23.9) | |
≥3 | 78 (82.1) | 43 (87.8) | 35 (76.1) | |
LDH (units/L) | 0.076 | |||
<420 | 39 (34.2) | 24 (42.1) | 15 (26.3) | |
≥420 | 75 (65.8) | 33 (57.9) | 42 (73.7) | |
NSE (ng/mL) | 0.010 | |||
<28.5 | 31 (37.3) | 21 (51.2) | 10 (23.8) | |
≥28.5 | 52 (62.7) | 20 (48.8) | 32 (76.2) | |
CYFRA21-1 (ng/mL) | 0.014 | |||
<2.4 | 42 (44.7) | 26 (57.8) | 16 (32.7) | |
≥2.4 | 52 (55.3) | 19 (42.2) | 33 (67.3) |
Overall suvival | Progression-free survival | |||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age (<65 yr vs. ≥65 yr) | 7.934 (2.579-24.413) | <0.001 | 0.968 (0.601-1.557) | 0.892 |
Gender (female vs. male) | 2.796 (0.320-24.457) | 0.353 | 7.425 (2.119-26.010) | 0.002 |
Stage (LD vs. ED) | 0.563 (0.190-1.664) | 0.299 | 1.105 (0.614-1.988) | 0.739 |
Chemotherapy (≥3 vs. <3) | 17.701 (4.209-74.445) | <0.001 | 8.148 (3.482-19.066) | <0.001 |
Response to first-line treatment (CR/PR vs. SD/PD) | 4.385 (1.329-14.463) | 0.015 | 1.894 (1.108-3.236) | 0.020 |
LDH (<420 units/L vs. ≥420 units/L) | 1.583 (0.635-3.946) | 0.325 | - | - |
NSE (<28.5 ng/mL vs. ≥28.5 ng/mL) | 2.511 (0.952-6.625) | 0.063 | - | - |
CYFRA21-1 (<2.4 ng/mL vs. ≥2.4 ng/mL) | 1.020 (0.407-2.554) | 0.967 | - | - |
SUVsum (<24.6 |
3.970 (1.471-10.715) | 0.006 | 2.296 (1.388-3.797) | 0.001 |
Characteristic | No. (%) (n=91) |
---|---|
Response | |
Complete (CR) | 3 (2.6) |
Partial (PR) | 44 (38.6) |
Stable disease | 27 (23.7) |
Progressive disease | 17 (14.9) |
Not evaluated | 23 (20.2) |
Objective response (CR+PR) | 47 (41.2) |
Values are presented as number (%). SUVsum, sum of standardized uptake value; ECOG, Eastern Cooperative Oncology Group; LD, limited disease; ED, extensive disease; LDH, lactate dehydrogenase; NSE, neuron-specific enolase. The median value of SUVsum.
HR, hazard ratio; CI, confidence interval; LD, limited disease; ED, extensive disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; SUVsum, sum of standardized uptake value. The median value of SUVsum.